Sociedad Americana de Hirudoterapia

Antithrombotic pharmacodynamics and metabolomics study in raw and processed products of Whitmania pigra

Pharmacology/metabolomics published in Heliyon (2024)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Research reportFarmacología salivalKui H et al. · Heliyon, 2024

Abstract

OBJECTIVE: As a traditional Chinese medicine, leech has obvious pharmacological activities in anticoagulantion and antithrombosis. Whitmania pigra Whitman (WP) is the most commonly used leech in the Chinese market. It is often used in clinical applications after high-temperature processing by talcum powder to remove the fishy taste and facilitate crushing. The anticoagulant and thrombolytic active ingredients are protein and polypeptide, which may denaturate and lose activity after high-temperature processing. The rationality of its processing has been questioned in recent years. This study aims to investigate the effect of talcum powder scalding on the antithrombotic activity of WP in vivo and to discuss its pharmacodynamic mechanism in vivo. METHODS: Raw and talcum-powdered processed WP were administered intragastrically for 14 days, and carrageenan was injected intraperitoneally to prepare a mouse model of tail vein thrombosis. The incidence rate of tail vein thrombosis and the thrombus area under pathological tissue sections were calculated to evaluate the antithrombotic effect between raw and processed WP. Non-targeted metabolomics was conducted using UPLC-Q-TOF/MS technology to analyze the changes of small molecule metabolites in the body after administration of WP. RESULTS: After intragastric administration, both the raw product and the processed product of WP could inhibit the thrombosis induced by carrageenan, and the processed product had a more apparent antithrombotic effect than the raw product. The administration of WP could regulate the changes of some small molecular metabolites, such as amino acids, lipids, and steroids, in Sphingolipid metabolism and Glycerophospholipid metabolism. CONCLUSIONS: Based on the results of pharmacodynamics and metabolomics, processed WP will not reduce the antithrombotic activity of WP. This study provided a scientific basis for the rational use of leeches.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Resumen

Compares raw versus talcum-processed Whitmania pigra in carrageenan-induced tail-vein thrombosis in mice. Both reduced thrombosis incidence; processed product had a more pronounced antithrombotic effect via altered sphingolipid and glycerophospholipid metabolism.

Por qué esto importa para la hirudoterapia

Este estudio comparó los efectos antitrombóticos in vivo de productos crudos frente a procesados (escaldado con polvo de talco) del preparado de medicina tradicional china a base de la sanguijuela Whitmania pigra. Utilizando un modelo murino de trombosis de la vena de la cola, los investigadores hallaron que ambas formas inhibieron la trombosis, con un efecto más aparente en el producto procesado, junto con cambios en vías metabólicas específicas. Esta investigación es relevante para el dominio de ASH porque evalúa la consistencia farmacodinámica y los mecanismos metabólicos de los preparados de sanguijuela, abordando las preocupaciones de calidad en la medicina tradicional con sanguijuelas. La salvedad es que se trata de un estudio en animales que evalúa extractos de sanguijuela administrados por vía oral, lo cual es distinto de la terapia con sanguijuelas medicinales vivas.

Citación

Antithrombotic pharmacodynamics and metabolomics study in raw and processed products of Whitman.

Kui H et al. · Heliyon, 2024

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.